The collaboration between SciSparc and Clearmind continues to yield positive results in its obesity and metabolic disorder program
See the original post:
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
The collaboration between Clearmind and SciSparc continues to yield positive results in its obesity and Metabolic disorder program
SOUTH SAN FRANCISCO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) products for cancer, today announced that it will participate in one upcoming investor conference in December.
Read the original:
Allogene Therapeutics Announces Participation in December Investor Conference
MIAMI, Dec. 01, 2023 (GLOBE NEWSWIRE) -- Avenue Therapeutics, Inc. (Nasdaq: ATXI) (“Avenue” or the “Company”), a specialty pharmaceutical company focused on the development and commercialization of therapies for the treatment of neurologic diseases, today announced that Amy Chappell, M.D., FAAN, will be presenting preclinical in vivo data evaluating BAER-101 using the SynapCell's Genetic Absence Epilepsy Rat from Strasbourg (“GAERS”) model of absence epilepsy at the American Epilepsy Society (AES) 2023 Annual Meeting in Orlando, FL on December 2, 2023.
See the original post here:
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
PALO ALTO, Calif., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced monthly revenue in November 2023 and provided certain preliminary unaudited financial results for gross and net sales for the one month ended November 2023 and year-to-date through November 30, 2023.
NRTX-1001 investigational treatment has been well tolerated in all initial subjects
Go here to read the rest:
Neurona Therapeutics Presents New Clinical Data from First Cohort in Ongoing Phase I/II Open-Label Trial of NRTX-1001 Cell Therapy for Drug-resistant...
Nicox SA Société anonyme with a registered capital of € 50,170,498
The rest is here:
Number of voting rights as of November 30, 2023
Virender Ahluwalia will serve as Interim Chief Financial Officer Virender Ahluwalia will serve as Interim Chief Financial Officer
See original here:
RetinalGeniX Technologies Inc. Announces Hiring of Interim CFO
Regulated Information
See the original post here:
Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC
CAMBRIDGE, Mass., Dec. 01, 2023 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced that, effective as of November 29, 2023 the Compensation Committee of the Board of Directors granted stock options to purchase an aggregate of 22,875 shares of Vor Bio’s common stock and restricted stock units (“RSUs”) representing the right to receive an aggregate of 34,313 shares of Vor Bio’s common stock to four newly hired employees. The foregoing stock options and RSUs were granted as material inducements to employment with Vor Bio in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted under the Vor Biopharma Inc. 2023 Inducement Plan (the “Inducement Plan”).
Read more:
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)